Top-Rated StocksTop-RatedNASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $1.44 +0.01 (+0.70%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Palisade Bio Stock (NASDAQ:PALI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palisade Bio alerts:Sign Up Key Stats Today's Range$1.43▼$1.4850-Day Range$1.35▼$2.2052-Week Range$1.32▼$2.86Volume1.99 million shsAverage Volume3.94 million shsMarket Capitalization$250.95 millionP/E RatioN/ADividend YieldN/APrice Target$9.83Consensus RatingBuy Company Overview Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and conditions associated with intestinal inflammation, impaired gut-barrier function and complications following surgery. The company’s lead product candidate is LB1148, an orally administered, non-absorbed pan-serine protease inhibitor. Palisade Bio is evaluating LB1148 for its potential to limit the harmful effects of digestive enzymes, reduce inflammation and support intestinal healing during the postoperative period. The program has been studied in clinical trials involving patients undergoing abdominal surgery, including research related to postoperative ileus and other complications that can delay recovery. Palisade Bio’s development activities are centered on advancing LB1148 through clinical testing and evaluating additional applications for the compound in gastrointestinal and surgical-care settings. As a development-stage biotechnology company, its products remain investigational and are not broadly marketed as approved therapies. The company is headquartered in the United States and focuses its clinical development efforts on markets governed by U.S. and international regulatory authorities.AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 357th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalisade Bio has a consensus price target of $9.83, representing about 582.9% upside from its current price of $1.44.Amount of Analyst CoveragePalisade Bio has only been the subject of 3 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palisade Bio are expected to decrease in the coming year, from ($0.23) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Palisade Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.38% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 13.76, which indicates bearish sentiment.Change versus previous monthShort interest in Palisade Bio has recently decreased by 2.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.77 News SentimentPalisade Bio has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Palisade Bio this week, compared to 4 articles on an average week.Search Interest8 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have sold 115.12% more of their company's stock than they have bought. Specifically, they have bought $190,700.00 in company stock and sold $410,226.00 in company stock.Percentage Held by Insiders0.07% of the stock of Palisade Bio is held by insiders.Percentage Held by Institutions11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesPalisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Price Target of $9.83 According to AnalystsOctober 3 at 4:28 AM | americanbankingnews.comPalisade Bio, Inc. Announces Pali-2108 to Be Featured in Four Presentations At United European Gastroenterology Week 2026September 30 at 3:22 AM | marketscreener.comMTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026September 28, 2026 | finance.yahoo.comPalisade Bio to Present Early PALI-2108 Clinical and Biomarker Data at UEG Week 2026September 28, 2026 | quiverquant.comQPalisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026September 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Palisade Bio (PALI) and Iovance Biotherapeutics (IOVA)September 25, 2026 | theglobeandmail.comHC Wainwright Reaffirms "Buy" Rating for Palisade Bio (NASDAQ:PALI)September 25, 2026 | americanbankingnews.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $2.35 at the beginning of the year. Since then, PALI shares have decreased by 38.7% and is now trading at $1.44. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.00. The company earned $0.50 million during the quarter, compared to analysts' expectations of $0.50 million. When did Palisade Bio's stock split? Palisade Bio shares reverse split on Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings8/10/2026Today10/03/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, PALI's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees14Year Founded2005Price Target and Rating Average Price Target for Palisade Bio$9.83 High Price Target$25.00 Low Price Target$5.00 Potential Upside/Downside+582.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.78 million Net MarginsN/A Pretax Margin-6,388.20% Return on Equity-33.47% Return on Assets-31.79% Debt Debt-to-Equity RatioN/A Current Ratio24.26 Quick Ratio24.26 Sales & Book Value Annual Sales$500 thousand Price / Sales501.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book1.66Miscellaneous Outstanding Shares174,271,000Free Float174,149,000Market Cap$250.95 million OptionableNot Optionable Beta1.61 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PALI) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
